FDA approves XFG-adapted COVID-19 vaccine
The 2026 to 2027 formulation aligns with FDA guidance on the preferred composition for COVID-19 vaccines beginning this fall.
-
By
-
Kathryn Wighton
-
August 28, 2026
-
-
1
The FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults 65 and older and high-risk patients aged 5 to 64.
-
2
The approval is for the 2026 to 2027 formulation targeting the XFG variant, based on FDA guidance.
-
3
The vaccine demonstrated immune responses against various circulating SARS-CoV-2 variants, including XFG and others.
-
4
COMIRNATY should not be given to individuals with a history of severe allergic reactions to the vaccine or its components.
-
5
Reported adverse events include injection-site reactions, fatigue, headache, and rare cases of myocarditis and pericarditis.
